Heterogeneity in PCa prognosis is currently observed via risk stratification, which involves the prostate-specific antigen (PSA) level, T stage, Gleason score, the percentage of positive biopsy sores and age (Chang et al., 2014). The gene discussed is KLK3; the disease is posterior cortical atrophy.